Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
Public ClinicalTrials.gov record NCT04490915. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment
Study identification
- NCT ID
- NCT04490915
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Enrollment
- 182 participants
Conditions and interventions
Conditions
Interventions
- Crinecerfont Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 15, 2020
- Primary completion
- Jul 18, 2023
- Completion
- Jul 31, 2027
- Last update posted
- May 10, 2026
2020 – 2027
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Neurocrine Clinical Site | Los Angeles | California | 90027 | — |
| Neurocrine Clinical Site | San Diego | California | 92123 | — |
| Neurocrine Clinical Site | San Francisco | California | 94143 | — |
| Neurocrine Clinical Site | Aurora | Colorado | 80045 | — |
| Neurocrine Clinical Site | Atlanta | Georgia | 30329 | — |
| Neurocrine Clinical Site | Indianapolis | Indiana | 46202 | — |
| Neurocrine Clinical Site | Bethesda | Maryland | 20982 | — |
| Neurocrine Clinical Site | Boston | Massachusetts | 02115 | — |
| Neurocrine Clinical Site | Ann Arbor | Michigan | 48109 | — |
| Neurocrine Clinical Site | Minneapolis | Minnesota | 55454 | — |
| Neurocrine Clinical Site | Rochester | Minnesota | 55905 | — |
| Neurocrine Clinical Site | St Louis | Missouri | 63110 | — |
| Neurocrine Clinical Site | Great Neck | New York | 11021 | — |
| Neurocrine Clinical Site | New York | New York | 10029 | — |
| Neurocrine Clinical Site | Winston-Salem | North Carolina | 27157 | — |
| Neurocrine Clinical Site | Tulsa | Oklahoma | 74135 | — |
| Neurocrine Clinical Site | Philadelphia | Pennsylvania | 19104 | — |
| Neurocrine Clinical Site | Pittsburgh | Pennsylvania | 15224 | — |
| Neurocrine Clinical Site | Dallas | Texas | 75390 | — |
| Neurocrine Clinical Site | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04490915, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 10, 2026 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04490915 live on ClinicalTrials.gov.